The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
May 2nd 2024
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL
June 11th 2021Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Duvelisib Approved in Europe for Relapsed/Refractory CLL or Follicular Lymphoma
The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.
Single-Hit TP53 Associated With Prolonged OS and PFS Vs Multi-Hit TP53 in Ibrutinib-Treated CLL
May 27th 2021Patients with chronic lymphocytic leukemia and single-hit TP53 mutations derived long-term responses with ibrutinib monotherapy, whereas patients with multi-hit TP53 aberrations had shortened progression-free survival.
OS and Time to Richter Transformation Linked With Age in Adolescent and Young Adults With CLL
May 26th 2021Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.
Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model
May 17th 2021The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.
Zanubrutinib Shows Noninferiority, Improved Safety Vs Ibrutinib in Relapsed/Refractory CLL
Zanubrutinib demonstrated noninferiority in objective response rates and a trend toward improved progression-free survival when compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies
Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.